|Awarded On||August 20, 2014|
|Title||CDK Inhibitors as Adjunctive to 5-FU and/or Radiation in Esophageal Adenocarcinoma- Assessment of Efficacy and Predictive Biomarkers|
|Award Mechanism||Individual Investigator|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Dipen Maru|
|Cancer Sites||Head and Neck|
Patients with esophageal adenocarcinoma localized to esophagus and surrounding lymph nodes are treated with chemotherapy and radiation followed by surgical resection of esophagus. In spite of this aggressive therapy, 5 year survival is poor (20-25%). There is a dire need to increase sensitization of tumor to chemoradiotherapy to improve survival of these patients. Cyclin dependent kinase 9 is a critical enzyme for maintenance of several proteins which affect cell death (apoptosis). We propose to study the utility of cyclin dependent kinase (CDK) inhibitors with CDK 9 inhibitory activities in increasing sensitivity of esophageal carcinoma to commonly used chemotherapeutic agent 5-Fluouracil (...